Preclinical Identification of Poorly Controlled COPD: Patients with a Single Moderate Exacerbation Matter Too

Area of Science:

• Pulmonary Medicine
• Primary Care Research
• Health Economics

Background:

• Chronic obstructive pulmonary disease (COPD) presents significant global health challenges, including high morbidity, mortality, and healthcare expenditures.
• Current COPD management guidelines may not adequately identify all high-risk patients, particularly those with single moderate exacerbations or frequent short-acting beta-agonist (SABA) use.
• This research builds upon prior findings to refine criteria for poor COPD control, aiming for earlier detection in primary care settings.

Purpose of the Study:

• To redefine criteria for poor COPD control by incorporating patients with at least one moderate exacerbation or frequent SABA use.
• To develop and validate a predictive model for early identification of high-risk COPD patients in primary care.
• To assess the impact of inhaler therapy frequency on COPD control.

Main Methods:

• A retrospective, multicenter study involving 110 COPD patients in Spain.
• Logistic regression and LASSO regularization were employed to identify key predictors of poor COPD control.
• Poor control was defined as experiencing at least one moderate exacerbation or using three or more SABA inhalers annually.

Main Results:

• The predictive model demonstrated high performance with an AUC-ROC of 0.978, sensitivity of 92.86%, and specificity of 87.50%.
• Key predictors effectively identified high-risk COPD patients, facilitating timely interventions.
• A statistically significant association was found between once-daily inhaler therapies and better COPD control (p = 0.008).

Conclusions:

• Refined criteria for COPD control, including moderate exacerbations and frequent SABA use, offer a practical tool for primary care risk stratification.
• Early identification of high-risk COPD patients can potentially reduce hospitalizations and healthcare costs.
• Further validation in larger cohorts is recommended to confirm the model's broader applicability in COPD management.